Success in the clinic would boost the RNA editing field as well as Wave. Broadly speaking, the technology is designed to edit specific sites in an RNA transcript without making permanent changes to a person’s genome.
It’s an approach that’s drawn interest from major players including Eli Lilly and Roche, as well as startups such as Ascidian Therapeutics. For its part, Wave signed a four-year development deal with GSK late last year that included $225 million in potential development and launch milestone payments for WVE-006.
